Command Palette

Search for a command to run...

Preprint WatchMildJune 6th, 2026

EGFR Inhibition Promotes Enteroendocrine Cell Differentiation Contributing To Treatment-Associated Diarrhea

Ramos, G. P.; Zeve, D.; Shepherd, A.; Saint-Denis, E.; Aldefer, O.; Frintu, B.; Dale, S.; Sharma, K.; Mohlmann, E.; Mannam, P.; Byers, M.; Terzian, J.; Ribeiro, C. D.; Silva Oliveira, L. F.; Borges, K. S.; O'Connell, A. E.; Carlone, D.; Florez, N.; Rao, M. E.; Breault, D. P.

EGFR inhibition promotes enteroendocrine cell differentiation, contributing to treatment-associated diarrhea.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

This preprint reports that EGFR inhibition promotes enteroendocrine cell differentiation in the intestinal epithelium and links that shift to treatment-associated diarrhea, a mechanistic account of a known on-target toxicity of EGFR blockade (bioRxiv, 10.64898/2026.06.02.729650). The Claidex record holds one EGFR failure, the BG-60366 EGFR chimeric degrader program in non-small cell lung cancer, which ended as a sponsor decision rather than on a toxicity or efficacy readout (bg-60366-egfr-cdac-nsclc-strategic-shutdown). The preprint neither contradicts nor replicates that operational decision, but it adds tolerability context that any EGFR-directed program should weigh, because gastrointestinal toxicity shapes the therapeutic window for this target class. Severity is graded MILD because the single indexed EGFR failure was non-mechanistic.

Abstract excerpt

Enteroendocrine cells (EECs) are specialized sensors of the gastrointestinal (GI) epithelium that regulate gut function and systemic metabolism through hormone secretion. The molecular pathways directing intestinal stem cell (ISC) differentiation into EECs are incompletely understood due, in part, to their rarity. We sought to identify novel regulators of human EEC differentiation using a high-throughput screen of FDA-approved drugs and human duodenal organoids. Two epidermal growth factor receptor inhibitors (EGFRi) commonly used in cancer therapy and known to cause GI side effects, erlotinib and lapatinib, emerged as strong inducers of EEC differentiation, dramatically increasing chromogranin A (CHGA) expression compared to controls, while maintaining ISC function and organoid growth. EGFRi-treated organoids revealed robust and broad upregulation of EEC hormones, including serotonin (5HT), motilin (MLN), and somatostatin (SST), among others. In agreement with these findings, analysis of a patient cohort with lung cancer revealed an association with erlotinib use and increased circulating levels of the above EEC hormones compared to matched controls. Supporting a direct effect of EGFRi on EEC differentiation, mice treated with erlotinib demonstrated increased EEC numbers and hormones and showed EGFRi-associated diarrhea (EAD), a limiting side effect of these medications. Mechanistically, EGFRi induced upregulation of interferon (IFN) signaling targets during early ISC-to-EEC differentiation. Consistent with this, inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) attenuated EGFRi-induced EEC differentiation. These findings provide important insight into EEC differentiation that could inform treatment strategies for EAD, metabolic diseases, and GI diseases.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.